Our clinical data demonstrated that UCA1 expression levels were significantly higher in EGFR-mutant NSCLC patients who developed acquired resistance to EGFR-TKIs compared with before treatment levels, suggesting that high expression of UCA1 may be a mechanism of resistance to EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.